Correlation of chromosomes 1p and 19q status and expressions of O6‐methylguanine DNA methyltransferase (MGMT), p53 and Ki‐67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study
Authors:
- 30 June 2009
- journal article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 35 (4) , 367-379
Abstract
Aims: The objective of the present study was to verify the correlation of chromosomes 1p and 19q status and expressions of O6‐methylguanine DNA methyltransferase (MGMT), p53 and Ki‐67 in diffuse gliomas of World Health Organization grades II and III. Methods: A series of 146 diffuse gliomas, including 45 oligodendrogliomas, 42 oligoastrocytomas and 59 astrocytomas, were analysed by denaturing high‐performance liquid chromatography for 1p and 19q status and by immunohistochemistry for MGMT, p53 and Ki‐67 expression patterns. The molecular alterations were then correlated with clinicopathological characteristics and with each other. Results: Loss of heterozygosity (LOH) on 1p, combined LOH on 1p and 19q, low MGMT expression and high Ki‐67 expression were associated with oligodendroglial tumours, whereas high p53 expression was associated with astrocytic and mixed tumours. LOH on 1p and low MGMT expression were associated with grade II oligodendroglial tumours, whereas high expressions of p53 and Ki‐67 were associated with grade III oligodendroglial tumours. In addition, high Ki‐67 expression was associated with grade III astrocytomas. LOH on 1p and LOH on 19q were associated with nontemporal oligodendroglial tumours. Nonrandom associations were found between LOH on 1p and LOH on 19q, MGMT expression and p53 expression, and MGMT expression and Ki‐67 expression, whereas mutual exclusions were found between LOH on 1p and 19q and p53 expression, and LOH on 1p and Ki‐67 expression. Conclusions: The present study revealed significant interrelationships of the investigated molecular alterations and clinicopathological characteristics in diffuse gliomas of World Health Organization grades II and III, which support a promising role of molecular markers in the diagnostic assessment of these neoplasms.Keywords
This publication has 46 references indexed in Scilit:
- Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*Brain Pathology, 2008
- Molecular genetic markers as predictors of response to chemotherapy in gliomasCurrent Opinion in Oncology, 2007
- Prognostic stratification of patients with anaplastic gliomas according to genetic profileCancer, 2006
- O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 CohortJournal of Clinical Oncology, 2006
- The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision makingJournal of Neurosurgery, 2006
- Survival analysis of presumptive prognostic markers among oligodendrogliomasCancer, 2005
- Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomasAnnals of Neurology, 2005
- Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInternational Journal of Cancer, 2004
- Cyclooxygenase‐2 in oligodendroglial neoplasmsCancer, 2003
- Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular SubsetsThe American Journal of Pathology, 2002